Bonesupport Holding AB
STO:BONEX

Watchlist Manager
Bonesupport Holding AB Logo
Bonesupport Holding AB
STO:BONEX
Watchlist
Price: 387 SEK 1.31% Market Closed
Market Cap: 25.5B SEK
Have any thoughts about
Bonesupport Holding AB?
Write Note

Bonesupport Holding AB
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bonesupport Holding AB
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Bonesupport Holding AB
STO:BONEX
PP&E Net
kr20.6m
CAGR 3-Years
11%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
PP&E Net
kr213.3m
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
PP&E Net
kr391m
CAGR 3-Years
35%
CAGR 5-Years
17%
CAGR 10-Years
16%
Probi AB
STO:PROB
PP&E Net
kr237.8m
CAGR 3-Years
22%
CAGR 5-Years
20%
CAGR 10-Years
61%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
PP&E Net
kr384m
CAGR 3-Years
-7%
CAGR 5-Years
-5%
CAGR 10-Years
13%
BioArctic AB
STO:BIOA B
PP&E Net
kr31.1m
CAGR 3-Years
-8%
CAGR 5-Years
27%
CAGR 10-Years
N/A
No Stocks Found

Bonesupport Holding AB
Glance View

Market Cap
25.8B SEK
Industry
Biotechnology

Bonesupport Holding AB, a Swedish company, has carved a niche for itself in the intricate world of orthopedic treatments and regenerative medicine. Founded in 1999, the company's journey is rooted in innovation and development of injectable bio-ceramic bone graft substitutes, primarily aimed at addressing bone voids and other skeletal maladies. The cornerstone of their business is the proprietary CERAMENT platform, which combines biocompatible, synthetic materials with a unique ability to promote bone healing and integration. By offering solutions that are resorbable and can enhance the regrowth of natural bone, Bonesupport targets clinicians and professionals in orthopedics, trauma, and spine surgery, offering them alternatives to traditional bone grafting methods. The company's products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V, differentiate themselves by also being antibiotic-eluting—allowing for the simultaneous treatment of bone diseases and infection mitigation. Bonesupport's revenue models revolve around both direct sales and leveraging distribution partnerships in key markets, including Europe, the United States, and emerging regions. The company channels substantial investments into research and development, seeking to broaden the clinical applications of their technologies thus driving adoption in the market. They benefit from a growing interest in minimally invasive treatments among healthcare providers, who aim to enhance patient outcomes while also controlling costs. By continuing to expand its product portfolio and advancing clinical evidence, Bonesupport maintains a competitive edge in skeletal health, translating innovation and efficacy into profitability and market growth. This strategic pursuit of advanced bone treatment technologies underscores their role in transforming standard medical practices, ensuring they remain at the forefront of bone health solutions.

BONEX Intrinsic Value
275.4 SEK
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Bonesupport Holding AB's PP&E Net?
PP&E Net
20.6m SEK

Based on the financial report for Sep 30, 2024, Bonesupport Holding AB's PP&E Net amounts to 20.6m SEK.

What is Bonesupport Holding AB's PP&E Net growth rate?
PP&E Net CAGR 5Y
6%

Over the last year, the PP&E Net growth was 4%. The average annual PP&E Net growth rates for Bonesupport Holding AB have been 11% over the past three years , 6% over the past five years .

Back to Top